A one-pot rapid detection kit and method for Candida ERG11 resistance gene based on CRISPR / Cas13a

By introducing a DNA lock and crRNA prehybridization regulatory mechanism into the CRISPR/Cas13a detection system, the problem of Cas13a background activation in the early amplification stage was solved, achieving highly sensitive and stable detection of Candida ERG11 resistance genes, which is suitable for rapid and accurate clinical testing.

CN123063544APending Publication Date: 2026-11-10NANJING MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202611294213.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-08-25
Publication Date
2026-11-10

AI Technical Summary

Technical Problem

Existing technologies struggle to simultaneously achieve both stability and sensitivity in CRISPR/Cas13a detection within a one-pot reaction system. This is particularly true for low-copy target samples, where early Cas13a background activation and signal output instability pose challenges, making it difficult to meet the need for rapid and accurate detection of Candida ERG11 resistance genes.

Method used

A regulatory system using DNA lock and crRNA prehybridization was adopted. By forming a partial RNA-DNA double-stranded structure, the background activation of Cas13a in the early stage of amplification was reduced, and the target RNA was gradually unlocked in response. Combined with LwaCas13a protein and fluorescent reporter molecule, a one-pot CRISPR/Cas13a detection system was constructed.

Benefits of technology

It enables rapid detection of Candida ERG11 resistance gene under constant temperature of 37℃, shortening the detection time to within 1 hour, with a concordance rate of 98.6% and a sensitivity of 98.9%. The equipment cost is reduced, making it suitable for point-of-care testing and resource-scarce areas.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123063544A_ABST
    Figure CN123063544A_ABST
Patent Text Reader

Abstract

This invention discloses a one-pot rapid detection kit and method for the Candida ERG11 resistance gene based on CRISPR / Cas13a. Targeting common resistance mutation sites in the Candida ERG11 gene, this invention designs specific RPA primers and crRNA, and innovatively introduces a DNA lock that specifically hybridizes with crRNA, constructing a one-pot reaction system compatible with RPA amplification and CRISPR / Cas13a detection. The kit can complete detection within 40 minutes at a constant temperature of 37°C, with a specificity greater than 98% for single-base mutations and a sensitivity of 10 copies / μL. It is simple to operate, with closed-tube reactions preventing aerosol contamination, making it suitable for rapid screening of resistance genes in clinical samples and providing an effective molecular detection tool for personalized medication decisions for Candida infections.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of biotechnology, specifically relating to a one-pot rapid detection kit and method for Candida ERG11 resistance gene based on CRISPR / Cas13a. Background Technology

[0002] Candida is a common opportunistic pathogen in clinical practice, especially in immunocompromised patients and those in intensive care, where bloodstream infections caused by it have a high incidence and mortality rate of 40%-60%. Triazole antibiotics (such as fluconazole) are first-line drugs for treating invasive candidiasis; however, the proportion of drug-resistant strains has been rising in recent years, becoming a significant threat to global public health. Studies have shown that Candida resistance to triazole antibiotics is closely related to amino acid residue mutations in the sterol 14α-demethylase encoded by the ERG11 gene, with typical mutation sites including Y132, K143, and F145. These mutations can significantly reduce the binding affinity of drugs to the target enzyme, leading to treatment failure. Therefore, rapid and accurate identification of ERG11 resistance gene mutations is of significant clinical value for optimizing antifungal medication and timely adjusting treatment regimens.

[0003] Currently, the routine methods for detecting Candida resistance in clinical practice mainly include the following categories, but each has significant technical defects: (1) Traditional culture-drug susceptibility test: This method is the "gold standard" for clinical testing, but its process depends on the isolation and culture of fungi, which usually takes 48-72 hours or even longer to obtain results, making it difficult to meet the needs of rapid clinical decision-making, especially unsuitable for critically ill patients with rapidly progressing disease; (2) Polymerase chain reaction (PCR) and its derivative technologies: including PCR sequencing, real-time quantitative PCR (qPCR), etc. Although these methods are faster than culture methods, they rely on sophisticated thermal cycling instruments, making them unsuitable for point-of-care testing or resource-scarce areas, and the operation process is complex, with limited ability to distinguish single base missense mutations (SNVs), especially in low-abundance or complex clinical samples (such as blood and urine), where false positives or false negatives are likely to occur. (3) Isothermal amplification technology: such as recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP), etc. While this type of technology achieves rapid isothermal amplification and simplifies equipment requirements, its core capabilities are still largely limited to the rapid enrichment of nucleic acids, with relatively weak ability to accurately genotype single-base mutations. Most isothermal amplification assays still employ stepwise operations, which also fail to effectively address the problem of aerosol contamination.

[0004] In recent years, the CRISPR / Cas system (especially the Cas13a protein) has been widely used in molecular diagnostics due to its excellent nucleic acid recognition specificity and signal amplification capabilities. After specifically recognizing target RNA under the guidance of crRNA, the Cas13a protein activates its non-specific "trans-cleavage" activity, efficiently cleaving reporter molecules in the system, thereby achieving signal output. Theoretically, combining isothermal amplification (such as RPA) with CRISPR / Cas13a detection can construct a rapid, isothermal, highly sensitive, and easy-to-operate integrated detection platform.

[0005] However, integrating RPA and Cas13a into a one-pot closed-loop reaction system presents a long-standing core technical bottleneck: once the Cas13a protein is activated (even at a low level by non-specific background RNA or primer dimers), its strong trans-cleavage activity immediately kicks in, continuously cleaving and consuming fluorescent reporter molecules and other nucleic acid components in the reaction system. This "premature activation" leads to two major problems: first, the reporter molecules are prematurely depleted before RPA amplification is complete, resulting in a weak or even no detection signal (false negative); second, non-specific cleavage of Cas13a may interfere with the efficiency of RPA amplification, reducing detection sensitivity. Therefore, conventional one-pot mixing systems are often unstable, have low signal-to-noise ratios, and are difficult to reliably detect in low-copy target samples.

[0006] To overcome the above bottlenecks, existing technologies have attempted to use physical partitioning (such as placing reagents separately in the cap and bottom of the tube and centrifuging them before the reaction) or optimize the buffer system. However, these strategies have failed to fundamentally solve the "temporal conflict between the two core steps of amplification and detection". It is difficult to reduce background activation in the early stage of amplification in a single tube system and achieve responsive unlocking and stable signal output after the target RNA gradually accumulates. Summary of the Invention

[0007] To address the shortcomings of existing technologies, the purpose of this invention is to provide a kit and method for one-pot rapid detection of the Candida ERG11 resistance gene based on CRISPR / Cas13a.

[0008] The technical solution adopted by this invention to solve its technical problem is:

[0009] In a first aspect, the present invention protects a one-pot detection kit for the Candida ERG11 resistance gene based on CRISPR / Cas13a, the kit comprising:

[0010] a) An RPA primer pair for amplifying the target region c.282 to c.465 of the ERG11 coding region of Candida albicans, wherein the target region includes the sequence shown in SEQ ID NO.12 or SEQ ID NO.13, wherein the 5′ end of the forward primer contains the T7 promoter sequence;

[0011] b) A CRISPR / Cas13a detection system comprising Cas13a protein, crRNA that specifically recognizes drug resistance mutation sites in the ERG11 gene, and ssRNA reporter molecules labeled with a fluorescent quenching group; preferably, the Cas13a protein is LwaCas13a protein.

[0012] c) T7 RNA polymerase; preferably, an rNTP mixture also containing ATP, CTP, GTP and UTP;

[0013] d) A regulatory system for reducing early Cas13a background activation and achieving target-responsive unlocking, wherein the regulatory system is a DNA lock pre-hybridized with crRNA. The DNA lock is a 15 nt single-stranded DNA oligonucleotide, anticomplementary to positions 1 to 15 of the 20 nt spacer sequence of crRNA, leaving positions 16 to 20 of the spacer sequence exposed and forming a 5 nt toe. During the construction of the one-pot reaction system, the DNA lock pre-hybridizes with crRNA to form a partially RNA-DNA double-stranded structure, thereby reducing background activation caused by the binding of crRNA to non-target nucleic acids in the early stages of amplification. When T7 RNA polymerase transcribes and produces target RNA containing the target mutation, the target RNA first binds to the exposed toe of the crRNA and then replaces the DNA lock through toe-mediated strand displacement, restoring the crRNA's ability to bind to the intact target RNA, thereby activating the paracleavage activity of LwaCas13a and cleaving the ssRNA reporter molecule to generate a fluorescent signal.

[0014] e) Magnesium acetate and RNase inhibitors.

[0015] In a specific implementation, the DNA lock is a 15 nt single-stranded DNA oligonucleotide, which is anticomplementary to positions 1 to 15 of the corresponding crRNA spacer sequence, forming a 5 nt exposed toe at positions 16 to 20 of the crRNA spacer sequence. The 3′ end of the DNA lock preferably has an inverted dT modification to reduce nonspecific elongation or degradation. The DNA lock structure is selected from at least one of the following:

[0016] a) SEQ ID NO.14, corresponding to the DNA lock of crRNA (SEQ ID NO.7, Y132F);

[0017] b) SEQ ID NO.15, corresponding to the DNA lock of crRNA (SEQ ID NO.8, Y132H);

[0018] c) DNA lock corresponding to SEQ ID NO.16, crRNA (SEQ ID NO.9, K143R);

[0019] d) DNA lock corresponding to SEQ ID NO.17 (SEQ ID NO.10, F145L);

[0020] e) SEQ ID NO.18, the DNA lock corresponding to crRNA (SEQ ID NO.11, F145S);

[0021] In a specific implementation, the ERG11 gene drug resistance mutation site is selected from at least one of Y132F, Y132H, K143R, F145L, and F145S.

[0022] In a specific implementation, the RPA primer pair is selected from at least one of the following:

[0023] a) A forward primer containing the sequence shown in SEQ ID NO.1 and a reverse primer containing the sequence shown in SEQ ID NO.2;

[0024] b) A forward primer containing the sequence shown in SEQ ID NO.3 and a reverse primer containing the sequence shown in SEQ ID NO.4;

[0025] c) A forward primer containing the sequence shown in SEQ ID NO.5 and a reverse primer containing the sequence shown in SEQ ID NO.6.

[0026] In a specific implementation, the sequence of the crRNA is selected from any one or more sequences shown in SEQ ID NO.7 to SEQ ID NO.11.

[0027] In a specific implementation, the ssRNA reporter molecule has the structure 5′-FAM-rUrUrUrUrUrU-BHQ1-3′, and its final concentration in a 50 μL reaction system is 200 nmol / L. The reporter molecule has a length of 6 nt.

[0028] In a more specific embodiment, the fluorophore of the ssRNA reporter molecule is selected from FAM, HEX, or Cy5; the quenching group is selected from BHQ1, BHQ2, or BHQ3, which match the corresponding fluorophore. The FAM-BHQ1 combination is preferred.

[0029] In a specific implementation, the kit also includes a reaction buffer system: the rNTP mixture contains ATP, CTP, GTP, and UTP, with the final concentrations of the four ribonucleoside triphosphates in the reaction system being 1.0 mmol / L. Magnesium acetate (MgOAc) concentration ranges from 12 mmol / L to 16 mmol / L. RNase inhibitor concentration is 1 unit / μL. The RPA E-mix and replenishment solution are made up according to the standard RPA formulation.

[0030] In a more specific embodiment, the present invention provides a one-pot CRISPR / Cas13a reaction system (single mutation detection unit), as follows:

[0031] In specific implementations, the kit may also contain disposable sealed reaction tubes or microfluidic cartridges that enable built-in reaction compartments and chip-type closed injection.

[0032] Secondly, the present invention also protects the use of the reagent kit described above in the following (A1) or (A2):

[0033] (A1) Application in the detection of Candida for non-disease diagnostic purposes;

[0034] (A2) Application in the preparation of products for detecting Candida.

[0035] In a specific implementation, the Candida is Candida albicans.

[0036] Thirdly, the present invention protects a one-pot detection method for Candida ERG11 resistance gene based on CRISPR / Cas13a for non-disease diagnostic purposes, characterized in that the method comprises the following steps:

[0037] (1) Provide each component of any of the kits described above and prepare a one-pot reaction system;

[0038] (2) Isothermal amplification: The reaction system was incubated at 37±1℃ for 30~60 minutes;

[0039] (3) Result interpretation: Based on the presence or absence or intensity of the fluorescence signal, determine whether there is an ERG11 gene drug resistance mutation in the sample to be tested.

[0040] In a specific implementation plan, the sample to be tested may be blood, plasma, urine, swabs, sputum, or isolated Candida strains, etc.

[0041] Beneficial effects

[0042] This invention provides a one-pot rapid detection kit and method for the Candida ERG11 resistance gene based on CRISPR / Cas13a, which has the following advantages compared with the prior art:

[0043] Validation with 217 clinical samples showed that the kit of this invention had a concordance rate of 96.8% with traditional drug susceptibility testing, and the actual concordance rate reached 98.6% after sequencing correction. The detection time was shortened from 48 to 72 hours for traditional methods to less than 1 hour. In the evaluation of plasmid standards, the detection system of this invention achieved a single-base discrimination accuracy of 98.9% for the target ERG11 drug resistance-related mutation, a non-target template cross-reactivity rate of 1.3%, and a wild-type template cross-reactivity rate of 0. The 37℃ isothermal reaction eliminates the need for a thermal cycler, reducing equipment costs from 50,000 to 200,000 yuan to less than 1,000 yuan, demonstrating broad application prospects. Attached Figure Description

[0044] Figure 1 Specificity analysis for the CRISPR / Cas13a detection system;

[0045] Figure 2 Sensitivity evaluation of the CRISPR / Cas13a-based detection system and comparison with qPCR control. Detailed Implementation

[0046] The present invention will be further described in detail below with reference to the embodiments. Unless otherwise specified, all reagents or instruments used are considered to be conventional products that can be purchased on the market.

[0047] This invention provides a one-pot rapid detection kit for Candida ERG11 resistance gene based on CRISPR / Cas13a, comprising the following components:

[0048] (1) RPA primer pairs: The 5′ end of the forward primer contains the T7 promoter sequence so that the amplified product can be directly transcribed. The forward primer sequences are shown in SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5 in the sequence listing, and the corresponding reverse primer sequences are shown in SEQ ID NO.2, SEQ ID NO.4, and SEQ ID NO.6. The working concentration range is 400 nmol / L to 600 nmol / L;

[0049] (2) crRNA probe set: including crRNAs that recognize ERG11 resistance-related mutation sites, the sequences of which are shown in SEQ ID NO.7 to SEQ ID NO.11. Each crRNA is pre-hybridized with the corresponding DNA lock at a molar ratio of 1:1.2. In the crRNA-DNA lock working solution, the concentration of crRNA is 2.5 μmol / L and the concentration of DNA lock is 3.0 μmol / L. 1.0 μL of the working solution is added to a single 50 μL reaction system to make the final concentrations of crRNA and DNA lock 50 nmol / L and 60 nmol / L, respectively. Multi-site detection uses independent reaction units. Only one type of crRNA-DNA lock complex is added to each reaction unit.

[0050] (3) Cas13a enzyme: LwaCas13a enzyme was used, with a final concentration of 50 nmol / L;

[0051] (4) T7 RNA polymerase: T7 RNA Polymerase (product number M0251S, enzyme activity concentration 50 U / μL) produced by New England Biolabs was used. 1.0 μL, i.e. 50 U, was added to each 50 μL reaction system.

[0052] (5) Fluorescent-quenched ssRNA reporter molecule: The structure is 5′-FAM-rUrUrUrUrUrU-BHQ1-3′, with the 5′ end modified with the fluorescent group FAM and the 3′ end modified with the quenching group BHQ1. The final concentration in a 50 μL reaction system is 200 nmol / L.

[0053] (6) Reaction buffer system: NTP mix concentration 1.0 mmol / L. Magnesium acetate (MgOAc) concentration range 12 mmol / L to 16 mmol / L. RNase inhibitor concentration 1 unit / μL. RPA E-mix and replenishment solution are made up according to the standard RPA formula;

[0054] (7) Reaction system specifications: Total reaction volume 50 μL, 2 μL of template nucleic acid added to each reaction;

[0055] (8) Reaction container: disposable sealed reaction tube, or microfluidic cartridge that can realize built-in reaction compartment and chip-type closed injection.

[0056] 1. Preparation method and key steps:

[0057] (1) Sample collection and preprocessing:

[0058] Collect clinical samples for testing, including plasma, urine, swabs, sputum, or isolated bacterial strains. Routine samples are treated with a rapid lysis buffer containing an RNase inhibitor for 5 to 10 minutes to obtain the extract. For viscous samples (sputum), add N-acetylcysteine ​​(NAC) at a concentration of 20 mmol / L and digest at 37°C for 5 to 15 minutes. For tissue samples, pretreat with collagenase at a concentration of 1 mg / mL at 37°C for 20 to 40 minutes, followed by lysis. After treatment, centrifuge to remove impurities to obtain the nucleic acid extract for testing; use 2 μL of the nucleic acid extract as a template for each 50 μL detection reaction.

[0059] (2) Preparation of RPA amplification premix:

[0060] The RPA amplification premix includes RPA Rehydration Buffer, RPA lyophilized enzyme preparation, and RPA amplification primers. The dNTPs required for RPA are provided by a commercially available RPA basic reaction system; no additional dNTPs are added. Preferably, the forward primer shown in SEQ ID NO.1 and the reverse primer shown in SEQ ID NO.2 are used to amplify the ERG11 target region containing the Y132F, Y132H, K143R, F145L, and F145S sites; primer pairs shown in SEQ ID NO.3 and SEQ ID NO.4, and SEQ ID NO.5 and SEQ ID NO.6 are used as alternative amplification primers. The storage concentration of both the forward and reverse primers is 10 μmol / L, and the final concentration in a 50 μL reaction system is 480 nmol / L.

[0061] (3) Preparation of crRNA-DNA lock regulation component and Cas13a detection premix:

[0062] The crRNA was synthesized using in vitro transcription. The complete crRNA was 56 nt in length, including a 36 nt direct repeat and a 20 nt spacer sequence. The 20 nt spacer sequence contained the identifying bases corresponding to the ERG11 resistance-related mutation, and the specific sequences are shown in SEQ ID NO.7 to SEQ ID NO.11. The crRNA sequence numbers are shown in SEQ ID NO.7 to SEQ ID NO.11. Before detection, the corresponding crRNA was pre-hybridized with a DNA lock in vitro to form a crRNA-DNA lock regulatory component. Subsequently, the LwaCas13a protein was mixed with the crRNA-DNA lock regulatory component in a predetermined ratio to form a detection premix. In a 50 μL reaction system, the final concentration of LwaCas13a protein was 50 nmol / L, and the final concentration of the fluorescent reporter molecule was 200 nmol / L. After adding the reporter molecule, the mixture was aliquoted and stored at -80 °C.

[0063] (4) Reaction assembly:

[0064] The RPA lyophilized enzyme preparation, RPA Rehydration Buffer, RPA primer pairs, T7 RNA polymerase, rNTP mixture, crRNA-DNA lock prehybridization working solution, LwaCas13a protein, RNase inhibitor, MgOAc, test sample nucleic acid, ssRNA-FAM-BHQ1 reporter molecule, and RNase-free ddH2O were added to a single sealed reaction vessel according to the amounts shown in Table 3 to form a one-pot CRISPR / Cas13a detection system. During preparation, all components except the test sample nucleic acid and MgOAc were added first, followed by 2 μL of the test sample nucleic acid, and finally 2.50 μL of MgOAc to start the reaction. The total reaction volume was 50 μL.

[0065] (5) Constant temperature incubation:

[0066] The sealed reaction tubes were incubated in a thermostat. The reaction temperature was 37±1℃. The incubation time was 40 minutes. RPA amplification rapidly generated double-stranded DNA containing the T7 promoter under isothermal conditions, which was then transcribed into RNA by T7 RNA polymerase.

[0067] (6) Cas13a identification and signal amplification:

[0068] When the transcribed RNA contains a drug resistance site mutation, the corresponding crRNA binds to it in a highly complementary manner and specifically activates the trans-cleavage non-specific cleavage activity of Cas13a, thereby cleaving the 5′-FAM-rUrUrUrUrUrU-BHQ1-3′ reporter molecule in the system, causing the fluorescent group to separate from the quenching group and generate a fluorescent signal.

[0069] (7) Signal detection and interpretation:

[0070] Real-time or endpoint detection was performed using the FAM channel of a portable or benchtop fluorescence reading device, with excitation wavelengths of 470–495 nm and emission wavelengths of 510–530 nm. The initial fluorescence value of each reaction well was used as the background to calculate ΔRFU = RFU. 40 min-RFU0 min; the mean ΔRFU of the same batch without template control plus 3 times the standard deviation is used as the positive determination threshold. When the sample ΔRFU is higher than the threshold and the positive control is valid, it is determined to be positive for the corresponding mutation.

[0071] The following examples illustrate preferred embodiments of the present invention, but the present invention is not limited thereto.

[0072] Example 1: Preparation of standards and related primers and probes for the Candida ERG11 target

[0073] 1.1 Preparation of Standards

[0074] Using the ERG11-A allele target region shown in SEQ ID NO.12 as the wild-type insert fragment, the wild-type insert fragment was cloned into the pUC57 vector to obtain a wild-type standard plasmid. Five mutant standard plasmids were constructed by introducing sequence-confirmed nucleotide substitutions corresponding to Y132F, Y132H, K143R, F145L and F145S in the same sequence background.

[0075] 1.2 Preparation of amplification primers, crRNA, DNA locks and probes

[0076] RPA amplification primers, crRNA, and corresponding DNA lock were designed based on the ERG11 gene sequence. All primers, crRNA, and DNA lock were chemically synthesized by Sangon Biotech (Shanghai) Co., Ltd., as detailed below:

[0077] RPA amplification primers: The forward primer has a T7 promoter sequence (TAATACGACTCACTATAGGG) added to the 5' end, including SEQ ID NO.1, SEQ ID NO.3, and SEQ ID NO.5; the corresponding reverse primers are SEQ ID NO.2, SEQ ID NO.4, and SEQ ID NO.6, respectively.

[0078] crRNA genome: all mutation sites were designed at positions 14-15 of the spacer region. Synthesized using in vitro transcription, it contains SEQ ID NO.7 ~ SEQ ID NO.11 targeting the Y132F, Y132H, K143R, F145L, and F145S mutations.

[0079] RNA probe: The sequence is FAM-UUUUUU-BHQ1, with the fluorescent group FAM labeled at the 5' end and the quenching group BHQ1 labeled at the 3' end.

[0080] Example 2: Establishment and optimization of a one-pot CRISPR / Cas13a isothermal detection system

[0081] 2.1 Prehybridization of the regulatory component (crRNA-DNA lock)

[0082] Based on the above technical solution, this embodiment describes the specific preparation method of the crRNA-DNA lock regulatory component. The crRNA and DNA lock will be pre-hybridized in vitro, and the hybridization system will be prepared according to Table 1.

[0083] Table 1 Hybridization system

[0084]

[0085] Place the prepared reaction tubes in a PCR instrument and set the annealing program: denature at 95℃ for 3 min; then slowly cool to 25℃ at a rate of 0.1℃ / s. Store the obtained hybridization products at 4℃ for later use.

[0086] 2.2 Preparation of a one-pot isothermal detection system

[0087] Prepare a one-pot CRISPR / Cas13a isothermal detection reagent according to Table 3 below. This invention establishes corresponding detection systems for different drug-resistant mutation sites in the ERG11 gene. The reaction composition of each detection system is basically the same, except that the RPA amplification primers and crRNA-DNA lock regulatory components are replaced according to different detection targets. The primers and crRNAs corresponding to each mutation site are shown in Table 2. The primer pairs shown in SEQ ID NO.3 / 4 and SEQ ID NO.5 / 6 can be used as alternative RPA primer pairs.

[0088] Table 2. Preferred primers and crRNAs for each mutation site

[0089]

[0090] Table 3. CRISPR / Cas13a isothermal reaction system (single tube reaction)

[0091]

[0092] 2.3 Isothermal Detection Procedure

[0093] Centrifuge the prepared sealed reaction tubes and place them in a real-time quantitative PCR instrument (such as ABI StepOne or Bio-Rad CFX96). Set the isothermal amplification program to 37℃ for 40 min; collect fluorescence signals in the FAM channel every 1 min. A positive result (containing a specific drug resistance mutation) is determined when a typical "S"-shaped amplification curve appears on the instrument software interface and the endpoint ΔRFU ≥ 2.0; otherwise, it is determined to be negative.

[0094] Example 3: High-specificity typing experiment based on single base mismatch

[0095] This embodiment aims to verify the ability of the one-pot CRISPR / Cas13a isothermal detection system of the present invention to distinguish single-base mutations (SNVs) in the Candida ERG11 gene, as well as the cross-reactivity rate to non-target wild-type sequences.

[0096] 3.1 Preparation and precise quantification of target nucleic acids

[0097] (1) Construction of standard plasmids: The wild-type fragment of the Candida ERG11 gene and the target fragment containing common drug resistance mutations (Y132F, Y132H, K143R, F145L, F145S) were cloned into the pUC57 vector backbone to construct one wild-type plasmid and five mutant plasmids.

[0098] (2) Sequence verification: All recombinant plasmids were transformed into E. coli DH5α competent cells, cultured overnight, and then extracted and purified using a plasmid miniprep kit. The purified products were subjected to bidirectional alignment by Sanger sequencing, which confirmed that the target region sequence was 100% correct and that no additional mutations were introduced.

[0099] (3) Quantification and Standardization: The concentration (ng / μL) of each plasmid was determined using a NanoDrop One micro-spectrophotometer. To eliminate loading errors, the above six plasmid standards were diluted with TE buffer containing 10 ng / μL of vector nucleic acid (such as salmon sperm DNA) and standardized to a working concentration of 10. 4 Copies / μL are available for later use.

[0100] 3.2 Construction of the cross-reactivity matrix

[0101] To comprehensively evaluate specificity, a 5×6 orthogonal detection matrix was designed:

[0102] (1) Preparation of premix: Five different isothermal detection premixes (Master Mix) were prepared. Each premix contained an RPA amplification component, LwaCas13a protein, 5′-FAM-rUrUrUrUrUrU-BHQ1-3′ reporter molecule and crRNA-DNA lock prehybridization complex for the corresponding mutation site.

[0103] (2) Sample addition: In a 96-well skirtless PCR plate, add 48 μL of the above 5 detection premixes to the corresponding reaction wells; then add 2 μL of 10% PCR solution to each well. 4 Template copies / μL, including 5 mutant plasmids and 1 wild-type plasmid, make the total reaction volume per well 50 μL.

[0104] (3) Control settings: Each reaction matrix is ​​set with a template-free control well (NTC, with 2 μL RNase-free ddH2O replacing the template), and each detection combination is set with 3 parallel replicates.

[0105] 3.3 Constant Temperature Detection and Data Acquisition

[0106] Seal the 96-well plate and briefly centrifuge it, then place it in a real-time quantitative PCR instrument. Set the isothermal amplification program: incubate at 37±1℃ for a total time of 40 minutes; collect the fluorescence signal in the FAM channel every 1 minute.

[0107] 3.4 Result Determination and Data Analysis

[0108] (1) Baseline subtraction and positive threshold: The background fluorescence of each well was calculated using the fluorescence values ​​at 1-5 minutes as the baseline. The net increase in fluorescence at the endpoint (ΔRFU) was defined as RFU at 40 minutes of reaction minus the RFU of the NTC. A positive amplification was defined as ΔRFU ≥ 2.0.

[0109] (2) Specificity Results: As shown in the attached figures of the specification, the specificity of the three ERG11 resistance mutation detection systems, Y132F, K143R, and F145L, was evaluated. Each detection system included a template-free control (NTC), a wild-type ERG11 template, a corresponding mutation template (Matched), and a non-target template (Non-target). The results showed that only the corresponding mutation template produced a significant fluorescent amplification signal, while the wild-type template, the non-target template, and the template-free control did not produce a significant fluorescent amplification signal. This indicates that the detection system constructed in this invention can accurately identify the corresponding ERG11 resistance mutation and has good detection specificity.

[0110] (3) Cross-reaction inhibition: As shown in the attached diagram of the instruction manual, three detection systems, Y132F, K143R, and F145L, were used to perform cross-detection with non-corresponding mutant templates and wild-type templates, respectively. The results showed that only the target mutant template could activate the corresponding crRNA-mediated Cas13a paracleavage activity, while the other templates did not produce obvious fluorescence signals, indicating that each detection system has good single-base resolution and there is no obvious cross-reaction between different detection systems.

[0111] Example 4: Analytical sensitivity (LOD) boundary experiment for extremely low abundance samples

[0112] This embodiment aims to evaluate the lowest detection limit of the CRISPR / Cas13a one-pot system under ideal conditions and verify its amplification stability under low-copy templates.

[0113] 4.1 Preparation of Concentration Gradient Series Standards

[0114] (1) Five recombinant plasmids of ERG11 resistance mutation, namely Y132F, Y132H, K143R, F145L and F145S, were constructed and verified by sequencing, and used as standards for evaluating analytical sensitivity. Their initial concentrations were determined.

[0115] (2) Anti-adsorption gradient dilution: In low-concentration nucleic acid operations, plasmids are very easy to adsorb onto the tube wall, causing false negatives. Use nuclease-free ultrapure water containing 0.1% Tween-20 and 10 ng / μL Poly(A) RNA as the diluent.

[0116] (3) A strict 10-fold serial dilution was performed to prepare six graded standard templates with concentrations of 10: 5 10 4 10 3 10 2 10 1 10 0 copies / μL.

[0117] 4.2 Assembly and Statistical Specification of the Limiting Concentration Reaction System

[0118] (1) Five detection systems were established respectively: Y132F, Y132H, K143R, F145L and F145S.

[0119] All detection systems used the reaction system described in Example 2, only the RPA amplification primers and crRNA-DNA lock regulation components for the corresponding detection targets were changed. The corresponding relationships are shown in Table 4.

[0120] Table 4. RPA amplification primers and crRNA-DNA lock regulatory components for detecting target sites.

[0121]

[0122] (2) Statistical design with multiple replicates: To comply with the statistical standards for sensitivity definition in in vitro diagnostic reagents (IVD), for the high concentration group (10... 5 Up to 10 3 For each concentration, 3 copies / μL were used; for the very low concentration group (10 copies / μL), 3 parallel replicates were set up; 2 Up to 10 0 To capture the Poisson distribution effect, 20 parallel replicates were set for each concentration.

[0123] (3) Add 48 μL of the reaction premix solution corresponding to the detection unit and 2 μL of standard template to each well, so that the total reaction volume of each well is 50 μL. At the same time, set up 10 template-free control (NTC) replicates to monitor environmental aerosol pollution.

[0124] 4.3 Isothermal Amplification and Dynamic Monitoring

[0125] Place the sealed reaction tube / plate in a fluorescence reader and incubate at 37±1℃ for 40 minutes. Continuously record the fluorescence signal generated by the FAM channel to generate a kinetic curve.

[0126] 4.4 Sensitivity Results and Detection Rate Analysis

[0127] The positive detection rate was calculated by dividing the number of positive reactions at each template concentration by the total number of reactions. The lowest template concentration with a positive detection rate of not less than 95% was defined as the analytical limit of detection for the corresponding detection unit. The detection results for each detection unit are shown in Table 5.

[0128] Table 5 Sensitivity Results and Detection Rate Analysis

[0129]

[0130] The results showed that all five corresponding mutant templates were detected by the corresponding detection units, with a positive detection rate of 100% (15 / 15). Among the 75 detection reactions of non-corresponding mutant templates and wild-type templates, only one reaction showed a weak positive signal, with a non-target cross-reaction rate of 1.3% (1 / 75). Of the 90 detection reactions, 89 were correctly identified, with a single-base mutation discrimination accuracy of 98.9% (89 / 90). These results demonstrate that the detection system described in this invention can distinguish between target mutant templates, non-corresponding mutant templates, and wild-type templates.

[0131] like Figure 2 As shown, the three representative detection units, Y132F, K143R, and F145L, are at 10 0 ~10 5 The fluorescence response increased with increasing template concentration across the range of copies / μL template concentration. Combined with the multi-well detection results in Table 5, the positive detection rate of the above detection units was not less than 95% at a template concentration of 10 copies / μL; however, the positive detection rate decreased significantly when the template concentration decreased to 1 copy / μL. Therefore, the analytical detection limit of the detection system of this invention was determined to be 10 copies / μL.

[0132] Example 5: Clinical Sample Testing

[0133] 5.1 Rapid extraction of Candida nucleic acid

[0134] Six positive blood culture samples (numbered S01–S06) from suspected Candida bloodstream infections collected clinically were selected as the subjects for testing. Nucleic acid was extracted from each sample after confirming the presence of Candida growth through blood culture.

[0135] (1) Take 200 μL of positive blood culture medium and place it in a 1.5 mL centrifuge tube. Centrifuge at 12000 rpm for 5 min, discard the supernatant and collect the bacterial pellet.

[0136] (2) Add 100 μL of rapid lysis buffer (containing 1% Triton X-100, 10 mmol / L Tris-HCl and RNase inhibitor) to the precipitate, and add an appropriate amount of glass beads (about 0.5 mm in diameter).

[0137] (3) Place it in a homogenizer and shake at 6 m / s for 30 seconds to break up the cell walls;

[0138] (4) Add 10 μL of proteinase K and incubate at 56°C for 10 min;

[0139] (5) Centrifuge at 12000 rpm for 2 min, and take the supernatant as the extracted total nucleic acid, which can be used directly as a template for subsequent detection.

[0140] 5.2 Isothermal testing of actual samples

[0141] Using the extracted nucleic acids numbered S01-S06 as templates, reaction tubes were prepared according to the reaction system in Table 3 of Example 2.

[0142] Place the reaction tube in a fluorescence instrument and record the fluorescence at a constant temperature of 37°C for 40 min.

[0143] The test results are as follows:

[0144] After 40 minutes of isothermal amplification and detection, among the six clinical samples, sample S01 showed a significant fluorescent amplification signal in the Y132F detection unit, indicating a positive result for the Y132F mutation; sample S04 showed a significant fluorescent amplification signal in the K143R detection unit, indicating a positive result for the K143R mutation. Samples S02, S03, S05, and S06 did not show significant fluorescent amplification signals in the Y132F, Y132H, K143R, F145L, and F145S detection units, indicating that the aforementioned target mutations were not detected.

[0145] Sanger sequencing results showed that sample S01 contained the Y132F mutation, sample S04 contained the K143R mutation, and the remaining four samples did not show any of the Y132F, Y132H, K143R, F145L, and F145S mutations covered by this kit. The detection results of the method of this invention on the above six samples are consistent with the Sanger sequencing results.

[0146] The preliminary results of this embodiment indicate that the method of the present invention can detect the covered ERG11 resistance-related mutations in Candida-positive blood culture samples, and the detection process can be completed under isothermal conditions of 37°C. Given that this embodiment only tested 6 clinical samples, the clinical sensitivity, clinical specificity, and applicability to different types of clinical samples still need further evaluation by expanding the sample size.

[0147] Example 6: Consistency evaluation of clinical isolate detection results

[0148] 6.1 Clinical isolates and detection methods

[0149] Twenty-one seventeen non-replicating Candida albicans clinical isolates, confirmed by routine culture and strain identification, were collected. The susceptibility of each isolate to fluconazole was determined using the broth microdilution method. Simultaneously, the Y132F, Y132H, K143R, F145L, and F145S mutations were detected using the CRISPR / Cas13a one-pot detection system described in this invention.

[0150] During testing, 2 μL of nucleic acid extract from each clinical isolate was added to 48 μL of the reaction premix solution for the corresponding detection unit, making the total reaction volume 50 μL for each test. The reaction tubes were placed in a fluorescence detector and reacted at 37±1℃ for 40 min, with FAM channel fluorescence signals acquired every 1 min. A positive control and a template-free control were included in each batch of tests.

[0151] Simultaneously, Sanger sequencing was performed on the ERG11 target region of 217 clinical isolates. The method of this invention allows personnel to complete the testing and result interpretation without knowing the drug susceptibility test or Sanger sequencing results.

[0152] 6.2 Comparison with traditional drug susceptibility test results

[0153] Of the 217 clinical isolates, 72 were determined to be resistant to fluconazole by traditional drug susceptibility testing, while 145 were sensitive. The detection results of the method of this invention are shown in Table 6.

[0154] Table 6. Consistency Evaluation of Clinical Isolation Results

[0155]

[0156] A total of 210 clinical isolates were obtained using the method of this invention, with results consistent with traditional drug susceptibility testing, achieving a concordance rate of 96.8% (210 / 217). Among them, 3 isolates identified as drug-resistant by drug susceptibility testing did not detect the target mutation covered by this kit, while 4 isolates identified as drug-sensitive by drug susceptibility testing detected the target ERG11 mutation.

[0157] 6.3 Comparison with Sanger sequencing results

[0158] Sanger sequencing results showed that among the 217 clinical isolates, 72 carried the ERG11 target mutations covered by this kit, including 25 strains with the Y132F mutation, 11 strains with the Y132H mutation, 19 strains with the K143R mutation, 10 strains with the F145L mutation, and 7 strains with the F145S mutation. A comparison of the method of this invention with the Sanger sequencing results is shown in Table 7.

[0159] Table 7. Method of the present invention and Sanger sequencing results

[0160]

[0161] A total of 214 clinical isolates were found to be consistent with the Sanger sequencing results using the method of this invention, with an overall concordance rate of 98.6% (214 / 217). Using the Sanger sequencing results as a reference, the detection sensitivity of the method of this invention for the above five target mutations was 98.6% (71 / 72), and the detection specificity was 98.6% (143 / 145).

[0162] Further analysis of the seven isolates whose drug susceptibility test results were inconsistent with those of the method of this invention revealed that two isolates were identified as drug-resistant by the drug susceptibility test, but Sanger sequencing did not detect the target mutations covered by this kit, suggesting that their drug resistance may be related to other ERG11 mutations or other drug resistance mechanisms; the other two isolates were identified as drug-sensitive by the drug susceptibility test, but Sanger sequencing confirmed that they carried the target ERG11 mutation. After Sanger sequencing correction, the overall concordance rate of the method of this invention increased from 96.8% to 98.6%.

[0163] The scope of protection of this invention is not limited to the above embodiments. Variations and advantages that can be conceived by those skilled in the art without departing from the spirit and scope of the inventive concept are included in this invention and are protected by the appended claims.

[0164]

[0165]

[0166]

[0167]

[0168]

Claims

1. A one-pot detection kit for Candida ERG11 resistance gene based on CRISPR / Cas13a, characterized in that, The kit includes: a) An RPA primer pair used to amplify the target region of the ERG11 coding region of Candida albicans, wherein the 5′ end of the forward primer in the RPA primer pair contains the T7 promoter sequence; b) CRISPR / Cas13a detection system, wherein the CRISPR / Cas13a detection system includes Cas13a protein, crRNA that specifically recognizes ERG11 resistance mutation sites, and ssRNA reporter molecules labeled with fluorescent-quenching groups; c) T7 RNA polymerase and a mixture of rNTPs containing ATP, CTP, GTP and UTP; d) A DNA lock prehybridized with the crRNA, wherein the DNA lock is inversely complementary to positions 1 through 15 of the crRNA spacer sequence; e) Magnesium acetate and RNase inhibitors.

2. The reagent kit according to claim 1, characterized in that, The DNA lock is a 15 nt single-stranded DNA oligonucleotide. The DNA lock is inversely complementary to positions 1 to 15 of the 20 nt spacer sequence of the corresponding crRNA, so that positions 16 to 20 of the crRNA spacer sequence form an exposed toe end of 5 nt in length. The 3′ end of the DNA lock has an inverted dT modification. Preferably, the DNA lock sequence is selected from at least one of SEQ ID NO.14-18.

3. The kit according to claim 1 or 2, characterized in that, The target region sequence of Candida albicans ERG11 includes that shown in SEQ ID NO.12 or SEQ ID NO.

13.

4. The reagent kit according to claim 1, characterized in that, The RPA primer pair is selected from at least one of the following: a) A forward primer containing the sequence shown in SEQ ID NO.1 and a reverse primer containing the sequence shown in SEQ ID NO.2; b) A forward primer containing the sequence shown in SEQ ID NO.3 and a reverse primer containing the sequence shown in SEQ ID NO.4; c) A forward primer containing the sequence shown in SEQ ID NO.5 and a reverse primer containing the sequence shown in SEQ ID NO.

6.

5. The reagent kit according to claim 1, characterized in that, The sequence of the crRNA is selected from any one or more sequences shown in SEQ ID NO.7 to SEQ ID NO.

11.

6. The reagent kit according to claim 1, characterized in that, The structure of the ssRNA reporter molecule is 5′-FAM-rUrUrUrUrUrU-BHQ1-3′.

7. The kit according to claim 1, characterized in that, In a 50 μL reaction system, the final concentrations of ATP, CTP, GTP, and UTP were 1.0 mmol / L, the final concentration of magnesium acetate was 12–16 mmol / L, and the amount of RNase inhibitor was 50 U / reaction.

8. The use of the kit according to any one of claims 1-7 in either (A1) or (A2): (A1) Application in the detection of Candida for non-disease diagnostic purposes; (A2) Application in the preparation of products for detecting Candida.

9. A one-pot detection method for Candida ERG11 resistance gene based on CRISPR / Cas13a for non-disease diagnostic purposes, characterized in that, The method includes the following steps: (1) Provide each component of the kit according to any one of claims 1-7, and prepare a one-pot reaction system; (2) Isothermal amplification: The reaction system was incubated at 37±1℃ for 30~60 minutes. (3) Result interpretation: Based on the presence or absence or intensity of the fluorescence signal, determine whether there is an ERG11 gene drug resistance mutation in the sample to be tested.

10. The method according to claim 9, characterized in that, The samples to be tested are blood, plasma, urine, swabs, sputum, and / or isolated Candida strains.